Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Invitae Corporation Common Stock (NY: NVTA )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Feb 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invitae Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Why Invitae Was Down 17.5% in May
The genetic testing company's growth isn't the kind that impresses Wall Street. 
Via The Motley Fool
Recap: Invitae Q1 Earnings
Shares of Invitae (NYSE:NVTA) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 21.25% over the past year to ($0.... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
Can Invitae Be the Winner-Take-Most in Genetic Testing?
Just like in poker, in some markets, the winner can take the whole pot. Can Invitae take home all the chips? 
Via The Motley Fool
Here's the Top Takeaway for Healthcare Investors Right Now
There are just three words to remember. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
EXCLUSIVE: Invitae CEO On Making Genetics Cost-Effective And Accessible
San Francisco-headquartered Invitae Corp (NYSE: NVTA) defines itself as medical genetics company seeking to bring comprehensive genetic information into mainstream medicine, with... 
Via Benzinga
These 7 Medical Stocks Are Breaking Down — The Sell Rule You Should Know
Former high-flyers Dexcom and Tandem Diabetes are among seven health care stocks breaking down right now, according to MarketSmith.com. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
Here's What Stood Out With Invitae's Q1 Results
It wasn't just the genetics company's soaring revenue growth. 
Via The Motley Fool
ARKK Stocks Breakdowns and Bounces
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today. 
Via Talk Markets
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
Invitae Shares Trading Lower As Q1 Earnings Lag Estimates, Contracting Margins
Invitae Corp (NYSE: NVTA) reported first-quarter FY21 results after the market closed Tuesday, wherein EPS loss of $0.63 came in worse than expectation of $0.... 
Via Benzinga
Here's Why Invitae's Q1 Revenue Soared 61%
Sales were strong, but the medical genetics company still missed analysts' bottom-line expectations. 
Via The Motley Fool
Invitae (NVTA) Q1 2021 Earnings Call Transcript
NVTA earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
Is Invitae a Buy?
Can this leading clinical gene testing company add muscle to your portfolio? 
Via The Motley Fool
Topics Electric Vehicles
Exposures Electric Vehicles
3 Top Healthcare Stocks to Buy in April
All three companies have enjoyed major growth catalysts since the start of 2021. 
Via The Motley Fool
Topics Economy
Exposures Economy
Let's Take A Look At This Weeks Top Performing Sectors
Investing in different stock sectors allows you to diversify your portfolio through targeted exposure from companies in specific segments of the economy. Utilizing sector-based... 
Via Benzinga
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.